Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)

被引：8
|
作者：
Perrot, Aurore [1 ]
Lauwers-Cances, Valerie [2 ]
Touzeau, Cyrille [3 ]
Decaux, Olivier [4 ]
Hulin, Cyrille [5 ]
Macro, Magaret [6 ]
Stoppa, Anne-Marie [7 ]
Chretien, Marie Lorraine [8 ]
Karlin, Lionel [9 ]
Mariette, Clara [10 ]
Jacquet, Caroline [11 ]
Roussel, Murielle [12 ]
Guillemot, Coralie [13 ]
Devlamynck, Laure [2 ]
Avet-Loiseau, Herve [14 ]
Moreau, Philippe [15 ]
Attal, Michel [16 ]
机构：
[1] Ctr Hosp Univ Toulouse, Serv Hematol, Toulouse, France
[2] CHU Toulouse, serv Epidemiol, USMR, Toulouse, France
[3] CHU Nantes, Hematol, Ctr Rech Cancerol & Immunol Nantes Angers CRCINA, Nantes, France
[4] CHU Rennes, Serv Hematol, Rennes, France
[5] Hop Haut Leveque, Univ Hosp, Pessac, France
[6] Ctr Hosp Univ CHU Caen, Caen, France
[7] Inst Paoli Calmettes, Marseille, France
[8] CHU Dijon, Serv Hematol Clin, Dijon, France
[9] Univ Claude Bernard Lyon 1, CHU Lyon Sud, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France
[10] CHU Grenoble, Serv Hematol, Grenoble, France
[11] CHRU Nancy, Vandoeuvre Les Nancy, France
[12] CHU Limoges, Hematol, Limoges, France
[13] IUCT Oncopole, Pharm Unite Essais Clin, Toulouse, France
[14] UPS, CHU Toulouse, Unite Genom Myelome, IUCT Oncopole, Toulouse, France
[15] CHU Nantes, Nantes, France
[16] Inst Univ Canc Toulouse Oncopole, Toulouse, France
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146040
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
464
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS).
    Sonneveld, Pieter
    Broijl, Annemiek
    Gay, Francesca
    Boccadoro, Mario
    Einsele, Hermann
    Blade, Joan
    Dimopoulos, Meletios A.
    Delforge, Michel
    Spencer, Andrew
    Hajek, Roman
    Schjesvold, Fredrik
    Lonergan, Sarah
    Smith, Elena
    Carson, Robin L.
    Crist, Wendy
    Garvin, Wendy S.
    Vermeulen, Jessica
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.
    Rodriguez-Otero, Paula
    Moreau, Philippe
    Dimopoulos, Meletios Athanasios
    Beksac, Meral
    Perrot, Aurore
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    van de Donk, Niels W. C. J.
    Schjesvold, Fredrik
    Delforge, Michel
    Einsele, Hermann
    Spencer, Andrew
    Lonergan, Sarah
    Vieyra, Diego
    Sitthi-Amorn, Anna
    Carson, Robin L.
    Blade, Joan
    Boccadoro, Mario
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study
    Kumar, S. K.
    Moreau, P.
    Bahlis, N.
    Facon, T.
    Plesner, T.
    Orlowski, R. Z.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Weisel, K.
    Raje, N.
    Tiab, M.
    Macro, M.
    Frenzel, L.
    Leleu, X.
    Wang, G.
    Krevvata, M.
    Carson, R.
    Borgsten, F.
    Usmani, S. Z.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 183 - 184
  • [34] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
    Kumar, Shaji K.
    Moreau, Philippe
    Bahlis, Nizar Jacques
    Facon, Thierry
    Plesner, Torben
    Orlowski, Robert Z.
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher P.
    Weisel, Katja
    Raje, Noopur
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Pei, Huiling
    Krevvata, Maria
    Carson, Robin
    Borgsten, Fredrik
    Usmani, Saad
    BLOOD, 2022, 140 : 10150 - 10153
  • [35] A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients
    Silvennoinen, Raija
    Waage, Anders
    Peceliunas, Valdas
    Schjesvold, Fredrik
    Anttila, Pekka
    Uttervall, Katarina
    Saily, Marjaana
    Putkonen, Mervi
    Carlson, Kristina
    Haukas, Einar
    Sankelo, Marja
    Partanen, Anu
    Szatkowski, Damian
    Hansson, Markus
    Marttila, Anu
    Svensson, Ronald
    Axelsson, Per
    Lauri, Birgitta
    Mikkola, Maija
    Karlsson, Conny
    Abelsson, Johanna
    Ahlstrand, Erik
    Sikio, Anu
    Nahi, Hareth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S157 - S157
  • [36] Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China
    Fu, Chengcheng
    Wang, Jing
    Yan, Lingzhi
    Jin, Song
    Shang, Jingjing
    Shi, Xiaolan
    Yao, Weiqin
    Yan, Zhi
    Wu, De-Pei
    BLOOD, 2023, 142
  • [37] MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)
    Kull, M.
    Grosicki, S.
    Yeh, S. -P.
    Huang, J. S. Y.
    Byun, J. M.
    DiRienzo, C.
    Viqueira, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 314 - 314
  • [38] MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab plus daratumumab plus lenalidomide (EDR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
    Grosicki, Sebastian
    Yeh, Su-Peng
    Huang, Jeffrey S. Y.
    Byun, Ja Min
    DiRienzo, Christine
    Viqueira, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
    Moreau, Philippe
    Facon, Thierry
    Usmani, Saad
    Bahlis, Nizar Jacques
    Raje, Noopur
    Plesner, Torben
    Orlowski, Robert Z.
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher P.
    Weisel, Katja
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Pei, Huiling
    Krevvata, Maria
    Carson, Robin
    Borgsten, Fredrik
    Kumar, Shaji K.
    BLOOD, 2022, 140 : 7297 - 7300
  • [40] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
    Moreau, P.
    Facon, T.
    Usmani, S. Z.
    Bahlis, N.
    Raje, N.
    Plesner, T.
    Orlowski, R. Z.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Weisel, K.
    Tiab, M.
    Macro, M.
    Frenzel, L.
    Leleu, X.
    Wang, G.
    Krevvata, M.
    Carson, R.
    Borgsten, F.
    Kumar, S. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 238 - 238
12345